Travere officer plans $6.3M stock sale in 2026

Travere Therapeutics, Inc. (TVTX) received a notice that officer William Rote plans to sell up to 96,198 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $6,328,866.42.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) received a notice that officer William Rote plans to sell up to 96,198 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $6,328,866.42. The planned sales are expected to occur on or about September 15, 2026 on NASDAQ. As context, 94,261,082 shares of common stock were outstanding, a baseline figure, not the amount being sold.

The shares to be sold were acquired via several equity compensation arrangements: 78,650 shares from the exercise of stock options, 9,128 shares from an employee stock purchase plan, and a total of 8,420 shares from restricted and performance stock units that vested between February 13, 2018 and January 31, 2024.

Key Figures

Shares to be sold: 96,198 shares Aggregate market value of planned sale: $6,328,866.42 Shares outstanding: 94,261,082 shares +5 more

8 metrics

Shares to be sold 96,198 shares Planned Rule 144 sale of Travere Therapeutics common stock

Aggregate market value of planned sale $6,328,866.42 Approximate market value of 96,198 shares to be sold

Shares outstanding 94,261,082 shares Travere Therapeutics common stock outstanding as reference baseline

Shares from stock option exercise 78,650 shares Portion of shares to be sold acquired via stock option exercise on September 15, 2026

Shares from employee stock purchase plan 9,128 shares Portion of shares to be sold acquired under the employee stock purchase plan

Shares from RSUs and PSUs 8,420 shares Portion of shares to be sold from restricted and performance stock units vesting 2018–2024

Planned sale date September 15, 2026 Approximate date of proposed NASDAQ sales under Rule 144

Date of notice September 15, 2026 Date the Rule 144 notice was signed and filed

Key Terms

Rule 144, restricted stock units, employee stock purchase plan, performance stock units

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

employee stock purchase plan financial

"The securities to be sold were acquired under the employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

performance stock units financial

"Performance Stock Units | Issuer | | | 3093 | 08/13/2021 | N/A"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Travere Therapeutics (TVTX)?

The filing states that officer William Rote plans to sell up to 96,198 shares of Travere Therapeutics common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $6,328,866.42, on or about September 15, 2026.

How many Travere Therapeutics (TVTX) shares are planned to be sold and at what value?

Up to 96,198 shares of Travere Therapeutics common stock are planned to be sold, with an approximate aggregate market value of $6,328,866.42, as indicated in the notice filed for planned Rule 144 sales.

How does the planned sale compare to Travere Therapeutics (TVTX) shares outstanding?

The notice lists 94,261,082 shares of Travere Therapeutics common stock outstanding. The planned sale of 96,198 shares is measured against this baseline outstanding figure, which is not itself being offered or registered in this notice.

What are the sources of the Travere Therapeutics (TVTX) shares being sold?

The planned sales cover 78,650 shares from the exercise of stock options, 9,128 shares acquired under an employee stock purchase plan, and a total of 8,420 shares from vested restricted stock units and performance stock units granted between 2017 and 2021.

When were the Travere Therapeutics (TVTX) equity awards that generated these shares granted or acquired?

The shares to be sold were acquired under the employee stock purchase plan on November 30, 2017 and November 30, 2024, and through vesting of restricted stock units and performance stock units granted on February 13, 2018 and August 13, 2021, vesting from February 13, 2018 through January 31, 2024.

Who is the broker for the planned Travere Therapeutics (TVTX) Rule 144 sales?

The planned Rule 144 sales of Travere Therapeutics common stock are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, New York.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:36 PM Accepted by SEC EDGAR 09/15/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001698262
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	WILLIAM ROTE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	96198	6328866.42	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			78650	09/15/2026	Cash
Common	11/30/2017	Employee Stock Purchase Plan	Issuer			9128	11/30/2017	Cash
Common	02/13/2018	Restricted Stock Units	Issuer			5327	02/13/2018	N/A
Common	08/13/2021	Performance Stock Units	Issuer			3093	08/13/2021	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 02/13/2018 through 01/31/2024. The securities to be sold were acquired under the employee stock purchase plan on 11/30/2017 and 11/30/2024.
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ William Rote
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)